TL;DR
Telehealth leader Hims & Hers confirmed on its February 23, 2026, earnings call that it is actively developing a peptide-based product line. This strategic move, underpinned by their 2025 acquisition of a dedicated peptide manufacturing facility, signals a major shift toward the mainstream adoption of peptide therapy, promising
